Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational Results available

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

ClinicalTrials.gov ID: NCT03933215

Public ClinicalTrials.gov record NCT03933215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Injectable DMDs for RMS (CLICK-MS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (DMDs) approved in the United States (US) for RMS in a real-world setting.

Study identification

NCT ID
NCT03933215
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Enrollment
100 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 20, 2019
Primary completion
Mar 29, 2024
Completion
Mar 29, 2024
Last update posted
Apr 28, 2025

2019 – 2024

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
HCA Research Institute Englewood Colorado 80113
Advanced Neurosciences Research Fort Collins Colorado 80528
Prairie Education & Research Springfield Illinois 62702
Fort Wayne Neurological Center Fort Wayne Indiana 46804
College Park Family Care Center Overland Park Kansas 66212
The Elliot Lewis Center for Multiple Sclerosis Care, LLC Wellesley Massachusetts 02481
UMASS - Neurology Worcester Massachusetts 01655
Henry Ford Health System Detroit Michigan 48202
Memorial Healthcare Owosso Michigan 48867
Minneapolis Clinic of Neurology - Neurology Minneapolis Minnesota 55422
Guilford Neurologic Associates Greensboro North Carolina 27405
Neurology Center of San Antonio San Antonio Texas 78258
Blacksburg Neurology, PC Christiansburg Virginia 24073
Neurological Associates Richmond Virginia 23229
VCU Medical Center - Pediatric Neurology Richmond Virginia 23298-0211
Sentara Ambulatory Care Center Virginia Beach Virginia 23456
MS Center of Evergreen Kirkland Washington 98034

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03933215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03933215 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →